(53) found SFTPC mutation in patients with both IPF and NSCLC (IPF-NSCLC) by Whole-exome analysis, and revealed that SFTPC mutation could notably decrease the expression of SFTPC. Here, we proved the expression of SFTPC was extremely decreased in clinical NSCLC samples, and we clarified that overexpression of SFTPC repressed EMT process of NSCLC cells via upregulating SOX7 and then inactivating WNT/β-catenin pathway. The gene discussed is SFTPC; the disease is non-small cell lung carcinoma.